Cited by 395Ovarian cancer diagnosis and treatmentPARP inhibition in cancer therapyCancer Treatment and Pharmacology

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

Monk, Bradley J., Herzog, Thomas J., Kaye, Stanley B., Krasner, Carolyn N., Vermorken, Jan B., Muggia, Franco M., Pujade-Lauraine, Eric, Lisyanskaya, Alla S., Makhson, Anatoly N., Rolski, Janusz, Gorbounova, Vera A., Ghatage, Prafull, Bidzinski, Mariusz, Shen, Keng, Ngan, Hextan Yuen-Sheung, Vergote, Ignace B., Nam, Joo-Hyun, Park, Youn Choi, Lebedinsky, Claudia A., Poveda, Andrés M.·2010·Journal of Clinical Oncology

DOI 10.1200/jco.2009.25.4037

Open this paper in CoChat — free account

Abstract

Purpose: The objective of this study was to compare the efficacy and safety of trabectedin plus pegylated liposomal doxorubicin (PLD) with that of PLD alone in women with recurrent ovarian cancer after failure of first-line, platinum-based chemotherapy. Patients and Methods: Women ≥ 18 years, stratified by performance status (0 to 1 v 2) and platinum sensitivity, were randomly assigned to receive an intravenous infusion of PLD 30 mg/m 2 followed by a 3-hour infusion of trabectedin 1.1 mg/m 2 every 3 weeks or PLD 50 mg/m 2 every 4 weeks. The primary end point was progression-free survival (PFS) by independent radiology assessment. Results: Patients (N = 672) were randomly assigned to trabectedin/PLD (n = 337) or PLD (n = 335). Median PFS was 7.3 months with trabectedin/PLD v 5.8 months with PLD (hazard ratio, 0.79; 95% CI, 0.65 to 0.96; P = .0190). For platinum-sensitive patients, median PFS was 9.2 months v 7.5 months, respectively (hazard ratio, 0.73; 95% CI, 0.56 to 0.95; P = .0170). Overall response rate (ORR) was 27.6% for trabectedin/PLD v 18.8% for PLD (P = .0080); for platinum-sensitive patients, it was 35.3% v 22.6% (P = .0042), respectively. ORR, PFS, and overall survival among platinum-resistant patients were not statistically different. Neutropenia was more common with trabectedin/PLD. Grade 3 to 4 transaminase elevations were also more common with the combination but were transient and noncumulative. Hand-foot syndrome and mucositis were less frequent with trabectedin/PLD than with PLD alone. Conclusion: When combined with PLD, trabectedin improves PFS and ORR over PLD alone with acceptable tolerance in the second-line treatment of recurrent ovarian cancer.

Integrity signals

Registry

Crossref · 10.1200/jco.2009.25.4037

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Global cancer statistics
Jemal, A., Bray, F., Ferlay, J., Ward, E., & Forman, D. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 55,077
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,710
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B. N., Wenzel, L. B., Huang, H. Q., Baergen, R. N., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,626
Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan
Gordon, A. N., Fleagle, J., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, Á. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,212
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
Parmar, M., Ledermann, J. A., Colombo, N., du Bois, A., Jf, D., Kristensen, G. B., Wheeler, S., Swart, A. M., Qian, W., Torri, V., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13718-x · Cited by 1,180
Comparisons between the National Comprehensive Cancer Network (NCCN) non-small-cell lung cancer (NSCLC) Clinical Practice Guidelines (Chinese version), the NCCN original edition, and the European Society for Medical Oncology NSCLC Guidelines in 2009
Xu, Y., Liu, H., Chen, J., & Zhou, Q. (2010) · Thoracic Cancer · doi:10.1111/j.1759-7714.2010.00016.x · Cited by 884
Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG
Pfisterer, J., Plante, M., Vergote, I. B., du Bois, A., Hirte, H. W., Lacave, Á. J., Wagner, U. A. G., Staehle, A., Stuart, G. C. E., Kimmig, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0913 · Cited by 752
Self-citation
Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.
Huinink, W. W. T. B., Gore, M. E., Carmichael, J., Gordon, A., Malfetano, J. H., Hudson, I., Broom, C., Scarabelli, C., Davidson, N. G. P., Spanczynski, M., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2183 · Cited by 662
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)
du Bois, A., Quinn, M. A., Thigpen, T., Vermorken, J. B., Åvall‐Lundqvist, E., Bookman, M. A., Bowtell, D. D. L., Brady, M. F., Casado, A., Cervantes, A. M. R., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi961 · Cited by 464
Self-citation
Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer
Gordon, A. N., Tonda, M. E., Sun, S. H., & RACKOFF, W. R. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.07.011 · Cited by 421
Hy's law: predicting serious hepatotoxicity
Temple, R. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1211 · Cited by 353
An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer
Greimel, E., Bottomley, A., Cull, A., Waldenström, A., Arrarás, J. I., Chauvenet, L., Holzner, B., Kuljanić, K., Lebrec, J., & D’haese, S. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00307-1 · Cited by 229
Trabectedin for Women With Ovarian Carcinoma After Treatment With Platinum and Taxanes Fails
Sessa, C., de Braud, F., Perotti, A., Bauer, J. A., Curigliano, G., Noberasco, C., Zanaboni, F., Gianni, L., Marsoni, S., Jimeno, J. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.032 · Cited by 162
Trabectedin: A Review of its Use in the Management of Soft Tissue Sarcoma and Ovarian Cancer
Carter, N. J., & Keam, S. J. (2007) · Drugs · doi:10.2165/00003495-200767150-00009 · Cited by 107
A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens
for the ET-743-INT-11 study group, Krasner, C. N., McMeekin, D. S., Chan, S. Y. T., Braly, P. S., Renshaw, F. G., Kaye, S. B., Provencher, D. M., Campos, S. M., & Gore, M. E. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604088 · Cited by 103
Self-citation
Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells.
Takahashi, N., Li, W. W., Banerjee, D., Scotto, K. W., & Bertino, J. R. (2001) · PubMed · Cited by 96
Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies
Riccardi, R., Meco, D., Colombo, T., Ubezio, P., Zucchetti, M., Zaffaroni, M., Riccardi, A., Faircloth, G. T., Jose, J., & D’Incalci, M. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0636-6 · Cited by 77
Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat.
Donald, S., Verschoyle, R. D., Greaves, P., Gant, T. W., Colombo, T., Zaffaroni, M., Frapolli, R., Zucchetti, M., D’Incalci, M., Meco, D., et al. (2003) · PubMed · Cited by 64
Clinical trial endpoints in ovarian cancer: Report of an FDA/ASCO/AACR Public Workshop☆
Bast, R. C., Thigpen, J. T., Arbuck, S. G., Basen‐Engquist, K., Burke, L. B., Freedman, R. S., Horning, S. J., Ozols, R. F., Rustin, G. J. S., & Spriggs, D. R. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.08.092 · Cited by 58
A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies
von Mehren, M., Schilder, R. J., Cheng, J. D., Temmer, E., Cardoso, T. M., Renshaw, F. G., Bayever, E., Zannikos, P., Yuan, Z., & Cohen, R. B. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn363 · Cited by 50
DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (ET-743)
Schöffski, P., Casali, P. G., Tarón, M., van Oosterom, A. T., Judson, I. R., Grosso, F., Blay, J., Maki, R. G., Tercero, J. C., Jimeno, J. M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.9522 · Cited by 25
2006 Update of ASCO Practice Guideline Recommendations for the Use of White Blood Cell Growth Factors: Guideline Summary
(2006) · Journal of Oncology Practice · doi:10.1200/jop.2006.2.4.196 · Cited by 16
Epithelial Ovarian Cancer
Copeland, L. J. (2007) · Elsevier eBooks · doi:10.1016/b978-032303978-9.50014-9 · Cited by 13
Health-related quality of life/patient-reported outcomes in relapsed ovarian cancer: Results from a randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone
Krasner, C. N., Poveda, A. M., Herzog, T. J., Vermorken, J. B., Monk, B. J., Zintl, P., Li, J., Su, Y., Dhawan, R., & Kaye, S. B. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.5526 · Cited by 10
Self-citation

Research works printed but not linked: 2

Takahashi N, 2001, Clin Cancer Res, 7, 3251
Donald S, 2003, Cancer Res, 63, 5902

Sorted by citations

Ovarian cancer
Matulonis, U. A., Sood, A. K., Fallowfield, L., Howitt, B. E., Sehouli, J., & Karlan, B. Y. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.61 · Cited by 1,362
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ledermann, J. A., Raja, F. A., Fotopoulou, C., González-Martı́n, A., Colombo, N., & Sessa, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt333 · Cited by 1,119
A Review on Antibiotic Resistance: Alarm Bells are Ringing
Zaman, S. B., Hussain, M. A., Nye, R., Mehta, V., Mamun, K. T., & Hossain, N. (2017) · Cureus · doi:10.7759/cureus.1403 · Cited by 866
Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
Germano, G., Frapolli, R., Belgiovine, C., Anselmo, A., Pesce, S., Liguori, M., Erba, E., Uboldi, S., Zucchetti, M., Pasqualini, F., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.008 · Cited by 887
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
Cherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., de Vries, E. G. E., & Piccart, M. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv249 · Cited by 818

See all 395

Authors: Monk, B. J., Herzog, T. J., Kaye, S. B., Krasner, C. N., Vermorken, J. B., Muggia, F. M., Pujade-Lauraine, E., Lisyanskaya, A. S., Makhson, A. N., Rolski, J., Gorbounova, V. A., Ghatage, P., Bidzinski, M., Shen, K., Ngan, H. Y.-S., Vergote, I. B., Nam, J.-H., Park, Y. C., Lebedinsky, C. A., & Poveda, A. M.
Affiliations: University of California, Irvine (US)
From the University of California at Irvine (UCI) and UCI Medical Center, Orange, CA; Columbia University College of Physicians and Surgeons; New York University Hospital, New York, NY; the Royal Marsden Hospital, Surrey, United Kingdom; Gillette Center for Women's Studies, Massachusetts General Hospital, Boston, MA; Antwerp University Hospital, Edegem; University Hospital, Leuven, Belgium; Université Paris Descartes, Assistance Publique Hôpitaux de Paris, Hôpital Hôtel-Dieu, Paris, France; SPBSIH City...
ORCID: Monk, Bradley J.
Herzog, Thomas J.
Vermorken, Jan B.
Muggia, Franco M.
Lisyanskaya, Alla S.
Ghatage, Prafull
Shen, Keng
Vergote, Ignace B.
Nam, Joo-Hyun
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2010-07-01
Volume: 28
Issue: 19
Pages: 3107-3114
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2009.25.4037
OpenAlex: W2125064537
Cited by: 395
References: 30
Citations by year: 2026: 2 · 2025: 4 · 2024: 9 · 2023: 10 · 2022: 17 · 2021: 25 · 2020: 18 · 2019: 13 · 2018: 25 · 2017: 41 · 2016: 26 · 2015: 32 · 2014: 37 · 2013: 40 · 2012: 37
FWCI: 51.61
Type: journal article
Language: en
Open access: closed
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
Keywords: trabectedin, pegylated liposomal doxorubicin, recurrent ovarian cancer, second-line chemotherapy, platinum-resistant ovarian cancer, platinum-sensitive ovarian cancer, progression-free survival, overall response rate, neutropenia, transaminase elevation, hand-foot syndrome, mucositis
MeSH terms: Trabectedin, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dioxoles, Doxorubicin, Drug Administration Schedule, Female, Humans, Leukopenia, Middle Aged, Neoplasm Recurrence, Local, Neutropenia, Ovarian Neoplasms, Polyethylene Glycols, Stomatitis, Multivariate Analysis, Treatment Outcome, Tetrahydroisoquinolines, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Citations

Cites

Cited by

Related

Metadata

Record

About these checks